熱門資訊> 正文
Qualigan Therapeutics收到纳斯达克关于延迟10-Q表格的通知
2025-05-20 05:35
- Qualigen Therapeutics (NASDAQ:QLGN) announced on Monday that it received an expected deficiency notification letter from Nasdaq.
- The notice indicated that the Nasdaq Hearings Panel will consider the company’s failure to timely file its quarterly report on Form 10-Q for the period ended March 31, 2025, as an additional basis for delisting the company’s securities from Nasdaq.
- The company said it intends to present its plan to regain compliance at the hearing and will continue to work diligently to complete and file the Form 10-Q as soon as practicable.
- Source: Press Release
More on Qualigen Therapeutics
- Financial information for Qualigen Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
